18F-Fluorodeoxyglucose positronemission tomography could have a prognostic role in patients with advanced Hepatocellular Carcinoma

Current Oncology

Volumn 21, Issue 4, 2014, Pages

  Simoneau, E ^a   Hassanain, M ^a,b   Madkhali, A ^b   Salman, A ^a   Nudo, C G ^a   Chaudhury, P ^a   Metrakos, Peter ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Hepatocellular carcinoma; Outcomes; Positron emission tomography; Prognosis

Indexed keywords

EID: 84905682132     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1959     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. [Erratum in: CA Cancer J Clin 2011;61:134]
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
3. Bruix J, Sherman M on behalf of the Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
4. Poon RT, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001;19:3037-44.
5. Paul SB, Gulati MS, Sreenivas V, et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 2007;72(suppl 1):117-23.
6. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001;2:157-64.
7. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Ver. 2.2012. Fort Washington, PA: nccn; 2012. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf (free registration required); cited January 13, 2014]
8. Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13:427-33.
9. Kim BK, Kang WJ, Kim JK, et al. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011;117:4779-87.
10. Huang WY, Kao CH, Huang WS, et al. 18F-fdg pet and combined 18F-fdg-contrast ct parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. J Nucl Med 2013;54:1710-16.
11. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with fdg-pet. J Nucl Med 1995;36:1811-17.
12. Pant V, Sen IB, Soin AS. Role of 18F-fdg pet ct as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun 2013;34:749-57.
13. Ahn SG, Kim SH, Jeon TJ, et al. The role of preoperative [18F] fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg 2011;15:2044-52.
14. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-7.
15. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7.
16. Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002;235:722-30.
17. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
18. Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of longterm survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005;100:2708-16.
19. Poon RT, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001;19:3037-44.
20. Mazzaferro V, Llovet JM, Miceli R, et al. on behalf of the Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
21. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-7.
22. Kornberg A, Freesmeyer M, Bärthel E, et al. 18F-fdg-uptake of hepatocellular carcinoma on pet predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009;9:592-600. [Erratum in: Am J Transplant 2009;9:1255]
23. Paudyal B, Oriuchi N, Paudyal P, et al. Early diagnosis of recurrent hepatocellular carcinoma with 18F-fdg pet after radiofrequency ablation therapy. Oncol Rep 2007;18:1469-73.
24. Sugiyama M, Sakahara H, Torizuka T, et al. 18F-fdg pet in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961-8.
25. Nagaoka S, Itano S, Ishibashi M, et al. Value of fusing pet plus ct images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 2006;26:781-8.
26. Hain SF, Fogelman I. Recent advances in imaging hepatocellular carcinoma: diagnosis, staging and response assessment: functional imaging. Cancer J 2004;10:121-7.
27. Siemerink EJ, Mulder NH, Brouwers AH, Hospers GA. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. Oncologist 2008;13:734-5.